"Anaplastic lymphoma receptor tyrosine kinase" trang 1 - tải miễn phí từ tailieuXANH
Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma
11    72    0
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: Study protocol

Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: Study protocol
8    75    0
A study of pathological characteristics of pediatric non-Hodgkin lymphoma based on 2008 version of the world health organization classification of lymphoid neoplasms at children’s hospital 1

A study of pathological characteristics of pediatric non-Hodgkin lymphoma based on 2008 version of the world health organization classification of lymphoid neoplasms at children’s hospital 1
7    49    0
Educational case: ALK-negative anaplastic large cell lymphoma

Educational case: ALK-negative anaplastic large cell lymphoma
5    64    0
Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: A multiinstitutional national retrospective study

Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: A multiinstitutional national retrospective study
5    50    0
Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
8    83    0
Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALKpositive anaplastic large-cell lymphoma

Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALKpositive anaplastic large-cell lymphoma
11    73    0
The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials
6    51    0
A retrospective study of alectinib versus ceritinib in patients with advanced non– small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

A retrospective study of alectinib versus ceritinib in patients with advanced non– small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
8    134    1
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial
10    47    1
Challenges of driving CD30-directed CAR-T cells to the clinic

Challenges of driving CD30-directed CAR-T cells to the clinic
8    71    0
báo cáo khoa học:

báo cáo khoa học: "A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma"
12    45    0
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced nonsmall cell lung cancer: A meta-analysis

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced nonsmall cell lung cancer: A meta-analysis
16    60    0
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials
17    48    0
Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion
10    46    0
ALK-rearranged lung squamous cell carcinoma responding to alectinib: A case report and review of the literature

ALK-rearranged lung squamous cell carcinoma responding to alectinib: A case report and review of the literature
5    114    0
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
10    89    0
RNA-based analysis of ALK fusions in nonsmall cell lung cancer cases showing IHC/ FISH discordance

RNA-based analysis of ALK fusions in nonsmall cell lung cancer cases showing IHC/ FISH discordance
9    57    0
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
9    48    0
Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer

Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer
5    59    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.